International Journal of Rheumatology

Research Article

The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Table 9

Gastric mucosal changes at EGD according to the administration of NSAID+LDASA and the rate of H. pylori detection.


Altered gastric mucosa	H. pylori	Patients receiving NSAID+LDASA		Patients not receiving NSAID+LDASA,		Comparison group,		P; OR; (95% CI)
		n = 20		n = 25		n = 12

Antral gastritis, n (%)	(+)	11 (68.8)	16 (80.0)	14 (70.0)	20 (80.0)	3 (60.0)	5 (41.7)	P₁ = 0.034; OR = 5.6 (95% CI 1.15-27.37)	P₂ = 0.56; OR = 1.47 (95% CI 0.18-11.72)	P₃ = 0.64; OR = 1 (95% CI 0.23-4.35)	P₄ = 0.61; OR = 0.94 (95% CI 0.23-3.92)
	(-)	5 (31.2)		6 (30.0)		2 (40.0)

Pangastritis, n (%)	(+)	2 (100.0)	2 (10.0)	5 (100.0)	5 (20.0)	2 (100.0)	2 (16.7)	P₁ = 0.48; OR = 0.56 (95% CI 0.07-4.57)	P₂ = 1	P₃ = 0.31; OR = 0.44 (95% CI 0.08-2.58)	P₄ = 1
	(-)	0		0		0

Gastric mucosal erosion, n (%)	(+)	4 (80.0)	5 (25.0)	3 (60.0)	5 (20.0)	2 (100.0)	2 (16.7)	P₁ = 0.47; OR = 1.67 (95% CI 0.27-10.33)	P₂ = 0.71; OR = 0 (95% CI 0-NaN)	P₃ = 0.48; OR = 1.33 (95% CI 0.33-5.45)	P₄ = 0.50; OR = 2.67 (95% CI 0.16-45.14)
	(-)	1 (20.0)		2 (40.0)		0

Gastric mucosal hemorrhage, n (%)	(+)	0	1 (5.0)	2 (100)	2 (8.0)	1 (100.0)	1 (8.3)	P₁ = 0.62; OR = 0.58 (95% CI 0.03-10.21)	P₂ = 0.5; OR = 0 (95% CI 0-NaN)	P₃ = 0.58; OR = 0.61 (95% CI 0.05-7.20)	P₄ = 0.33; OR = 0 (95% CI 0-NaN)
	(-)	1 (100.0)		0		0

Intact gastric mucosa, n (%)	(+)	0	1 (5.0)	1 (50.0)	2 (8.0)	2 (50.0)	4 (33.3)	P₁ = 0.05; OR = = 9.5; (95% CI 0.91-98.81)	P₂ = 0.60; OR = 0 (95% CI 0-NaN)	P₃ = 0.58; OR = 0.61 (95% CI 0.05-7.20)	P₄ = 0.67; OR = 0 (95% CI 0-NaN)
	(-)	1 (100.0)		1 (50.0)		2 (50.0)

Notes: The percentage of patients with appropriate GM changes in the NSAID+LDASA, non-NSAID+LDASA, and comparison groups was calculated from the total number of patients in the corresponding group.
The percentage of H. pylori-positive patients was calculated from the number of those with appropriate GM changes in the NSAID+LDASA, non- NSAID+LDASA, and comparison groups.
Р₁ –comparison of the number of patients with and without appropriate GM changes in the comparison and NSAID+LDASA groups.
Р₂ – comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the comparison and NSAID+LDASA groups.
Р₃ – comparison of the number of patients with and without appropriate GM changes in the NSAID+LDASA and non-NSAID groups.
Р₄ – comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the NSAID+LDASA and non- NSAID groups.